The conversation covers the science of egg quality and chromosome division in plain terms, why IVF outcomes have changed so little in decades and what a new class of reproductive therapeutics could mean for patients. Jordan also talks about founding a company without a university spin-out, raising capital at the earliest stage, leading a team of specialists and the lab problem that tennis balls helped solve. The discussion closes on where he sees the company in ten years and how AI is shaping biotech and business.
Listen to episode three on Spotify or Apple Podcasts or visit the BioX podcast page to stay tuned for future episodes.